In this Perspectives article, Aliza Thompson from the FDA's Division of Cardiovascular and Renal Products argues that existing data do not support the adoption of proteinuria as a general-purpose surrogate end point for establishing a drug's effectiveness in treating chronic kidney disease. She suggests, however, that it may be reasonable to use changes in proteinuria as a basis for the accelerated approval of a drug if certain conditions are met.
